{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Import Library\n",
    "\n",
    "import openai\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import AzureDeveloperCliCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.indexes import SearchIndexClient\n",
    "from azure.search.documents.indexes.models import (\n",
    "    HnswParameters,\n",
    "    PrioritizedFields,\n",
    "    SearchableField,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticField,\n",
    "    SemanticSettings,\n",
    "    SimpleField,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmConfiguration,\n",
    ")\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "from azure.core.exceptions import ResourceExistsError\n",
    "import json\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "#from langchain.retrievers import AzureCognitiveSearchRetriever\n",
    "from langdetect import detect\n",
    "from langchain.prompts import PromptTemplate\n",
    "import re\n",
    "# Create chain to answer questions\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "# Import Azure OpenAI\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.schema import HumanMessage\n",
    "\n",
    "#import textwrap\n",
    "import logging\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"#setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"gptdemosearch\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"PcAZcXbX2hJsxMYExc2SnkMFO0D94p7Zw3Qzeu5WjYAzSeDMuR5O\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"sino-hr-chatbot\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\"\"\"\n",
    "\n",
    "# setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"acs-testing-sunny\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"oygYftyrBXiWoDLoZatDKNSLFttn9frM6DE4XlSb7kAzSeBR01eY\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"your-index-name\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 5 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the page where your answer is based on \n",
    "    5. Please provide the page number in the following output format: [Page: 1]\n",
    "    \n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    \n",
    "    文本：{context}\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "def initialize_vector_store():\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "    \n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "    \n",
    "    return vector_store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "def azure_search_by_index(question, index_name):\n",
    "\n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "\n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    lang = detect(context)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    #page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "    \n",
    "    #print(relevant_documentation[0])\n",
    "    #print(source)\n",
    "    #print(page_no)\n",
    "    #print(website_url)\n",
    "    #return str(context), source, website_url, lang, page_no\n",
    "    # just return 10 documents (i.e. pages) if number of pages return from the search result > 10\n",
    "    if len(relevant_documentation) > 10:\n",
    "        relevant_documentation = relevant_documentation[0:9]\n",
    "    else:\n",
    "        relevant_documentation = relevant_documentation\n",
    "    return relevant_documentation, source, website_url, lang, page_no\n",
    "\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import LLMChain\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.memory import CosmosDBChatMessageHistory\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 6 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context and the chat history below\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
    "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3]\n",
    "    6. Allow the chat continue by following Chat History\n",
    "    \n",
    "    Chat History: {chat_history}\n",
    "\n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    5. 通过谈话记录允许聊天继续\n",
    "    \n",
    "    文本：{context}\n",
    "\n",
    "    谈话记录：{chat_history}\n",
    "\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import ConversationalRetrievalChain\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    elif \"(Page:\" in string: # handling for exception\n",
    "        print(re.findall('\\(Page:.*\\)', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\(Page:.*\\)', string)[0].split(':')[1].split(\")\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n",
    "\n",
    "def llm_pipeline_with_history(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    language = detect(question)\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "    else:\n",
    "        QA_CHAIN_PROMPT = generate_prompt_chi_with_history()\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    \"\"\"    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\"\"\n",
    "    \n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://acs-testing-sunny.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"UyxAxYPy6nhqLoTVhbs7C8NknhHoaRJuFkBaZramSAEPzNsHU0dhanOTRr2AJOjtqA1m0d5N3ujkACDbNmxrAQ==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"acs-fda-sunny\"\n",
    "    CONTAINER_NAME = \"acs-fda-cosmo\"\n",
    "\n",
    "    # session id, to be provided by frontend\n",
    "    sessionId = \"103\"\n",
    "    user_id = \"guest\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "    vector_store =initialize_vector_store()\n",
    "    \n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    #lang = detect(question)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    #page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "\n",
    "    retriever = vector_store.as_retriever()\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "\n",
    "    # The chain\n",
    "    chain = ConversationalRetrievalChain.from_llm(\n",
    "        llm,\n",
    "        retriever=retriever,\n",
    "        memory=memory,\n",
    "        combine_docs_chain_kwargs={\"prompt\": QA_CHAIN_PROMPT},\n",
    "        verbose=True,\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = PromptTemplate.from_template(template)\n",
    "\n",
    "    output = chain({\"question\": question})\n",
    "    \n",
    "    logging.info(output)\n",
    "    answer_value = output[\"answer\"]\n",
    "    # \n",
    "    language = \"-\"\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "        \n",
    "    logging.info(page_no)\n",
    "\n",
    "    if page_no == \"/\" or page_no == \"N/A\":\n",
    "        source = \"-\"\n",
    "        website_url = \"/\"\n",
    "\n",
    "    # extract first page number\n",
    "    if \",\" in page_no:\n",
    "        first_page_no  = page_no.split(\",\")[0]\n",
    "    else:\n",
    "        first_page_no = page_no\n",
    "    \n",
    "    page_no = extract_page_no(answer_value)\n",
    "    answer = extract_answer(answer_value)\n",
    "    \n",
    "    #return answer_value\n",
    "    \n",
    "    json_response = {\n",
    "        \"raw\": output,\n",
    "        \"answer\": answer,\n",
    "        \"source\": source,\n",
    "        \"website_url\": website_url,\n",
    "        \"page_no\": page_no,\n",
    "        \"first_page_no\": first_page_no,\n",
    "        \"language\": language\n",
    "    }\n",
    "    return json_response\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mGiven the following conversation and a follow up question, rephrase the follow up question to be a standalone question, in its original language.\n",
      "\n",
      "Chat History:\n",
      "\n",
      "Human: 你知道什么是生物利用度吗?\n",
      "Assistant: 生物利用度（BA）是指药物在体内被吸收并达到活性部位的程度。它是衡量药物在体内的吸收速度和程度的指标。生物等效性（BE）是指不同药物制剂或不同批次的同一药物制剂在体内的吸收是否相似。生物等效性研究是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收情况。这些研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度。 [Page: 187, 190]\n",
      "Human: what is the name of the document?\n",
      "Assistant: I'm sorry, I don't have access to the specific document you are referring to.\n",
      "Human: What is PK? \n",
      "Assistant: Yes, PK (pharmacokinetic) studies are used to measure the concentration and absorption rate of a drug in the body. These studies are a method to assess the extent and rate of absorption of a drug in vivo. PK measures, such as AUC (area under the curve), Cmax (maximum concentration), and Tmax (time to reach maximum concentration), are used to evaluate the systemic exposure and absorption rate of a drug. PK studies are commonly used in bioavailability (BA) and bioequivalence (BE) studies to compare different drug formulations or batches and determine if they have similar absorption profiles. [Page: 202, 209]\n",
      "Follow Up Input: 你知道什么是生物等效性吗? \n",
      "Standalone question:\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new StuffDocumentsChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3m\n",
      "    指令：\n",
      "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
      "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
      "    3. 请以少於200字回答问题。\n",
      "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
      "    \n",
      "    文本： \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      "   Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "640 For example, in some instances, in vivo BA or BE  is self-evident based on certain characteristics \n",
      "641 of the drug product (21 CFR 320.22(b )), and therefore, any in vi vo data requirement has been \n",
      "642 deemed to have been met.  In other delineated circumstances, an in vivo BA or BE data \n",
      "643 requirement may be waived, and in vitro data may be accepted in lieu of in vivo data (21 CFR \n",
      "644 320.22(d)). For example, an in vivo data requirem ent may be waived for different strengths of \n",
      "645 an immediate-release drug product under 21 CF R 320.22(d)(2) when (1) the drug product is in \n",
      "646 the same dosage form, but in a different strength;  (2) this different strength is proportionally \n",
      "647 similar in its active and inactive ingredient s to another drug product for which the same \n",
      "648 manufacturer has obtained approval;  and (3) the new strength meets an appropriate in vitro test \n",
      "649 as outlined in the regulation.26 In addition, for waiving higher strengths, linearity of the \n",
      "650 pharmacokinetics over the therapeutic dose range should be demonstrated. \n",
      "651 \n",
      "652 This guidance defines proportionally similar in the following ways: \n",
      "653 \n",
      "654  All active and inactive ingredients are in exactly the same proportion between different \n",
      "655 strengths (e.g., a tablet of 50-mg strength has al l the inactive ingredient s, exactly half that \n",
      "656 of a tablet of 100-mg strength, and twice that of a tablet of 25-mg strength). \n",
      "657 658  For high-potency drug substances (where the amount of active dr ug substance in the \n",
      "659 dosage form is relatively low), (1) the total weight of the dosage form remains nearly the \n",
      "660 same for all strengths (within ± 10 % of the to tal weight of the strength on which a BE \n",
      "661 was performed), (2) the same inactive ingredie nts are used for all st rengths, and (3) the \n",
      "662 change in any strength is obtained by altering the amount of the active ingredients and \n",
      "663 one or more of the inactive ingredients.   \n",
      "664 665  Bilayer tablets are considered to be one formulation even though they consist of two \n",
      "666 separate layers with different compositions.  In assessing the proportional similarity of \n",
      "667 the different strengths, all components of both layers should be proportionally similar.  \n",
      "668 The fact that only one layer is proportionally si milar and the other is not clearly indicates \n",
      "669 that the products (whole tablet) are not propor tionally similar. This is relevant because \n",
      "670 there can be interactions between the different tablet layers, which can differ across \n",
      "671 different strengths because of the different size of the layers and the varying amounts of \n",
      "672 excipients present in each layer. \n",
      "673 \n",
      "674 Exceptions to the above definitions may be possibl e if adequate justification is provided and \n",
      "675 discussed with the appropriate review division. \n",
      "676 \n",
      "677 B. In Vitro Studies Conducted in Support of Demonstrating BA or BE \n",
      "678 \n",
      "26 See also 21 CFR 322.22(d)(3) and (4) for additional bases for waiver.  Also, FDA, for good cause, may waive a \n",
      "requirement for the submission of evidence of in vivo bioa vailability or bioequivalence if waiver is compatible with \n",
      "the protection of the public health.  For full NDAs, FDA may defer a requirement for the submission of evidence of \n",
      "in vivo bioavailability if deferral is compatible with the protection of the public health (21 CFR 320.22(e)). \n",
      "17\n",
      " \n",
      "\n",
      " \n",
      " \n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "853 use the highest strength of the combination product with matching doses of individual \n",
      "854 drug products. \n",
      "855 \n",
      "856  Certain alternative study designs may also be acceptable depending on the specific \n",
      "857 situation. For instance, in the case of  a combination product consisting of two \n",
      "858 components, a three-treatment study desi gn comparing the combination drug product \n",
      "859 versus single-ingredient drug products admi nistered separately may be appropriate. \n",
      "860 861  A single-dose, food-effect study on the combination drug product. \n",
      "862 \n",
      "863 BE studies for the combination product s hould include the measurement of systemic \n",
      "864 concentrations of each active ingredient.  The co nfidence interval approach should be applied to \n",
      "865 each measured entity of the combination drug product and its reference product.  \n",
      "866 867 In specific cases, drug products are given in comb ination (not co-formulated) with the objective \n",
      "868 of increasing the exposure of one of the drugs (s ubject drug).  The second drug is not intended to \n",
      "869 have a therapeutic effect and is given only to in crease the systemic exposure of the subject drug.  \n",
      "870 When both the subject and second drug are new mo lecular entities, the BA of each should be \n",
      "871 assessed separately. If a BE study is needed for the subject drug for any reason, the subject drug \n",
      "872 should be administered with the second drug for both test and reference products.  The \n",
      "873 corresponding PK results, includi ng confidence intervals for BE crite ria, should be applied to the \n",
      "874 subject drug. It is not necessa ry to measure the concentrations  of the second drug.  BE studies \n",
      "875 that are needed for the second drug should be conducted only with the second drug; the subject \n",
      "876 drug is not dosed with the second drug.  When the combination includes a new molecular entity \n",
      "877 and an approved product, only the BA of the new molecular entity should be assessed.  It is \n",
      "878 assumed that the BA of the approved product has been previously evaluated.    \n",
      "879 \n",
      "880 G. Endogenous Substances \n",
      "881 \n",
      "882 Drug products can be developed that contain compounds that are endog enous to humans (e.g., \n",
      "883 testosterone). When the endogenous compounds are identical to the drug that is being \n",
      "884 administered, determining the amount of drug re leased from the dosage form and absorbed by \n",
      "885 each subject is difficult. In most cases, it is important to measure and approximate the baseline \n",
      "886 endogenous levels of the compound in blood (plasma)  and subtract these levels from the total \n",
      "887 concentrations measured from each subject after the drug product is administered.  In this way, \n",
      "888 an estimate of actual drug availability from the drug product can be achieved, and therefore BA \n",
      "889 and BE can be assessed. Endogenous substances may have homeostatic processes that affect \n",
      "890 their production and therefore imp act their systemic concentrati ons. To reduce the complication \n",
      "891 of these homeostatic processes and to potentia lly avoid the need for baseline correction, an \n",
      "892 alternative approach might be to  enroll patients in BA and BE studies with low or no production \n",
      "893 of the endogenous substances in stead of healthy volunteers. \n",
      "894 895 Baseline concentrations of th e endogenous substance produced by the body are measured in the \n",
      "896 time period prior to study drug administra tion.  Depending on the proposed indication, \n",
      "897 subtraction of the time-averaged baseline or time-matched baseline from the post-dose \n",
      "22\n",
      " \n",
      "\n",
      " \n",
      " Draft — Not for Implementation \n",
      " \n",
      "Contains Nonbinding Recommendations \n",
      " \n",
      "97 ingredients and/or active moieties over time and, when appropriate, active metabolites over time  \n",
      "98 in samples collected from the systemic circul ation.  Systemic exposure profiles reflect both \n",
      "99 release of the drug substance from the drug product  and a series of possibl e presystemic/systemic \n",
      "100 actions on the drug substance after its  release from the drug product.   \n",
      "101  \n",
      "102 FDA’s regulations at 21 CFR 320.25 set forth guidelines for in vivo BA studies.  As provided in \n",
      "103 this regulation, the reference product for BA st udies should be a solution, suspension, or \n",
      "104 intravenous (IV) dosage form (21 CFR 320.25(d)(2 ) and (3)).  The purpose of conducting a BA \n",
      "105 study with an oral solution as a reference is  to assess the impact of formulation on BA. \n",
      "106 Conducting a BA study with an IV reference enables assessment of the impact of route of \n",
      "107 administration on BA and defines the absolute BA of the drug released from the drug product. \n",
      "108    \n",
      "109  \n",
      "110 C.  Bioequivalence \n",
      "111  \n",
      "112 As noted previously, both BA and BE focus on the release of a drug substance from a drug \n",
      "113 product and subsequent absorption into systemic circulation.  As a resu lt, we recommend that \n",
      "114 approaches to determining BE generally follow approaches similar to those used for BA.  \n",
      "115 Demonstrating BE involves a more formal comparat ive test that uses spec ific references with \n",
      "116 specified criteria for comparisons and pr edetermined BE limits for such criteria.  \n",
      "117   \n",
      "118 1.  Preapproval Changes \n",
      "119  \n",
      "120 BE documentation can be useful during the IND period to compare (1) early and late \n",
      "121 clinical trial formulations; (2) formulations used  in clinical trials a nd stability studies, if \n",
      "122 different; (3) clinical trial formulations a nd to-be-marketed drug products, if different; \n",
      "123 and (4) product strength equi valence, as appropriate.  In each comparison, the new \n",
      "124 formulation, formulation produced by the ne w method of manufacture, or new strength is \n",
      "125 the candidate, or test product and the prior formulation, prior met hod of manufacture, or \n",
      "126 prior strength is the reference product.  The decision to document BE during drug \n",
      "127 development is generally left to the judgme nt of the sponsor, using the principles of \n",
      "128 relevant guidances (in this guidance, see sections II.C.2, Postapproval Changes, and \n",
      "129 III.D, In Vitro Studies) to determine when changes in components, composition, and/or \n",
      "130 method of manufacture suggest that further in vitro and/or in vivo studies be performed. \n",
      "131  \n",
      "132 2.  Postapproval Changes \n",
      "133  \n",
      "134 In the presence of certain ma jor changes in components, co mposition, manufacturing site, \n",
      "135 and/or method of manufacture after approval, FDA recomme nds that in vivo BE be \n",
      "136 demonstrated for the drug product after the change in comparison to the drug product \n",
      "137 before the change. Under section 506A(c)(2) of the Federal Food, Drug, and Cosmetic \n",
      "138 Act (FD&C Act) (21 U.S.C. 356a(c)(2)), certain postapproval ch anges that require \n",
      "139 completion of studies must be submitted in a supplement and approved by FDA before \n",
      "140 distributing a drug product made with the change. \n",
      "141  \n",
      "4\n",
      " \n",
      "\n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "142 Information on the types of recommended in vi tro dissolution and in vivo BE studies for \n",
      "143 immediate-release and modified-release dr ug products approved as NDAs for specified \n",
      "144 postapproval changes is provided in the following FDA guidances : \n",
      "145 \n",
      "146  SUPAC-IR: Immediate Release Solid Or al Dosage Forms:  Scale-Up and \n",
      "147 Postapproval Changes: Chemistry, Manufacturing, and Control; In Vitro \n",
      "148 Dissolution Testing, and In Vivo  Bioequivalence Documentation \n",
      "149  SUPAC-MR: Modified Release Solid Oral  Dosage Forms:  Scale-Up and \n",
      "150 Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro \n",
      "151 Dissolution Testing, and In Vivo  Bioequivalence Documentation \n",
      "152 \n",
      "153 3. BE Considerations \n",
      "154 \n",
      "155 BE studies are usually conducted using a cross over design.  For such studies, intrasubject \n",
      "156 variability should be considered  when determining the study sample size.  In cases when \n",
      "157 a parallel design is necessary to evaluate BE, consideration shoul d be given to total \n",
      "158 variability, including intersubject variability in stead of just intrasub ject variability.   \n",
      "159 160 A test product might fail to demonstrate bioequivalence because it ha s measures of rate \n",
      "161 and/or extent of absorption compared to th e reference product outside acceptable higher \n",
      "162 or lower limits. For example, when the test product results in a syst emic exposure that is \n",
      "163 significantly higher than that of  the reference product, the concern is the typically limited \n",
      "164 experience from a safety standpoint for higher systemic concentrations.  When the test \n",
      "165 product has a systemic exposure that is signif icantly lower than that of the reference \n",
      "166 product, the concern is potentially a lack of therapeutic efficacy of the test product.  \n",
      "167 When the variability of the test product is gr eater than the reference product, the concern \n",
      "168 relates to both safety and efficacy, because it may suggest that the performance of the test \n",
      "169 product is not comparable to the referen ce product, and the test product may be too \n",
      "170 variable to be c linically useful. \n",
      "171 \n",
      "172 When BE is not demonstrated, the sponsor shoul d demonstrate that the differences in rate \n",
      "173 and extent of absorption do not significantl y affect the safety and efficacy based on \n",
      "174 available dose-response or concen tration-response data.  In th e absence of this evidence, \n",
      "175 failure to demonstrate BE may suggest that the test product should be reformulated, or \n",
      "176 the method of manufacture for the test product should be changed, or additional safety or \n",
      "177 efficacy data may be needed for the test product.  In some cases, conclusions of BE based \n",
      "178 on the peak drug concentration (C\n",
      "max) and area under the plasma concentration time curve \n",
      "179 (AUC) between the test product and the reference product may be insufficient to \n",
      "180 demonstrate that there is no difference in safe ty or efficacy if the systemic concentration­\n",
      "181 time profiles of the test product and the refere nce product are different (e.g., time to reach \n",
      "182 peak drug concentration (T max) is different). For example, differences in the shape of the \n",
      "183 systemic concentration profile between the te st and reference produc ts could imply that \n",
      "184 the test product may not produce the same clin ical response as the reference product.  In \n",
      "185 such cases, additional data analysis (e.g., partial AUCs), exposure-re sponse evaluation, or \n",
      "186 clinical studies may be recommended to evaluate the BE of  the two products. \n",
      "5\n",
      " \n",
      "\n",
      "    谈话记录：\n",
      "Human: 你知道什么是生物利用度吗?\n",
      "Assistant: 生物利用度（BA）是指药物在体内被吸收并达到活性部位的程度。它是衡量药物在体内的吸收速度和程度的指标。生物等效性（BE）是指不同药物制剂或不同批次的同一药物制剂在体内的吸收是否相似。生物等效性研究是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收情况。这些研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度。 [Page: 187, 190]\n",
      "Human: what is the name of the document?\n",
      "Assistant: I'm sorry, I don't have access to the specific document you are referring to.\n",
      "Human: What is PK? \n",
      "Assistant: Yes, PK (pharmacokinetic) studies are used to measure the concentration and absorption rate of a drug in the body. These studies are a method to assess the extent and rate of absorption of a drug in vivo. PK measures, such as AUC (area under the curve), Cmax (maximum concentration), and Tmax (time to reach maximum concentration), are used to evaluate the systemic exposure and absorption rate of a drug. PK studies are commonly used in bioavailability (BA) and bioequivalence (BE) studies to compare different drug formulations or batches and determine if they have similar absorption profiles. [Page: 202, 209]\n",
      "\n",
      "    #####\n",
      "\n",
      "    问题：生物等效性是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收是否相似的指标。\n",
      "\n",
      "    \u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      " 202, 209]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'raw': {'question': '你知道什么是生物等效性吗? ',\n",
       "  'chat_history': [HumanMessage(content='你知道什么是生物利用度吗?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='生物利用度（BA）是指药物在体内被吸收并达到活性部位的程度。它是衡量药物在体内的吸收速度和程度的指标。生物等效性（BE）是指不同药物制剂或不同批次的同一药物制剂在体内的吸收是否相似。生物等效性研究是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收情况。这些研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度。 [Page: 187, 190]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='what is the name of the document?', additional_kwargs={}, example=False),\n",
       "   AIMessage(content=\"I'm sorry, I don't have access to the specific document you are referring to.\", additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='What is PK? ', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='Yes, PK (pharmacokinetic) studies are used to measure the concentration and absorption rate of a drug in the body. These studies are a method to assess the extent and rate of absorption of a drug in vivo. PK measures, such as AUC (area under the curve), Cmax (maximum concentration), and Tmax (time to reach maximum concentration), are used to evaluate the systemic exposure and absorption rate of a drug. PK studies are commonly used in bioavailability (BA) and bioequivalence (BE) studies to compare different drug formulations or batches and determine if they have similar absorption profiles. [Page: 202, 209]', additional_kwargs={}, example=False),\n",
       "   HumanMessage(content='你知道什么是生物等效性吗? ', additional_kwargs={}, example=False),\n",
       "   AIMessage(content='回答：是的，生物等效性是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收是否相似的指标。生物等效性研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度，以评估药物的系统暴露和吸收速度。这些研究可以通过比较AUC（曲线下面积）、Cmax（最大浓度）和Tmax（达到最大浓度的时间）等PK指标来确定药物的吸收情况是否相似。 [Page: 202, 209]', additional_kwargs={}, example=False)],\n",
       "  'answer': '回答：是的，生物等效性是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收是否相似的指标。生物等效性研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度，以评估药物的系统暴露和吸收速度。这些研究可以通过比较AUC（曲线下面积）、Cmax（最大浓度）和Tmax（达到最大浓度的时间）等PK指标来确定药物的吸收情况是否相似。 [Page: 202, 209]'},\n",
       " 'answer': '回答：是的，生物等效性是用来比较不同药物制剂或不同批次的药物制剂在体内的吸收是否相似的指标。生物等效性研究通常使用药物动力学（PK）方法来测量药物在体内的浓度和吸收速度，以评估药物的系统暴露和吸收速度。这些研究可以通过比较AUC（曲线下面积）、Cmax（最大浓度）和Tmax（达到最大浓度的时间）等PK指标来确定药物的吸收情况是否相似。 ',\n",
       " 'source': 'Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-—-General-Considerations.pdf',\n",
       " 'website_url': '/',\n",
       " 'page_no': '202, 209',\n",
       " 'first_page_no': '',\n",
       " 'language': '-'}"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"你知道什么是生物等效性吗? \"\n",
    "\n",
    "llm_pipeline_with_history(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_chat_history(history):\n",
    "    i = 0\n",
    "    for message in history.messages:\n",
    "        if i % 2 == 0:\n",
    "            print(\"Human: \" + message.content)\n",
    "        else:\n",
    "            print(\"AI: \" + message.content)\n",
    "        i+=1\n",
    "\n",
    "\n",
    "retrieve_chat_history(history)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show azure-search-documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# do not run, not use this for memory\n",
    "\n",
    "def llm_pipeline(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    #print(relevant_docs)\n",
    "\n",
    "    # generate prompt without example\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        PROMPT = generate_prompt()\n",
    "    else:\n",
    "        PROMPT = generate_prompt_chi()\n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\n",
    "    sessionId = \"101\"\n",
    "    user_id = \"Sunny\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    chain = LLMChain(llm=llm, \n",
    "                    prompt=PROMPT,\n",
    "                    memory=memory\n",
    "                   #verbose=True\n",
    "                    )\n",
    "\n",
    "    output = chain.run({\"context\": relevant_docs, #\"context\": relevant_docs, \n",
    "        \"question\": question,\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install azure-cosmos"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
